Literature DB >> 15183092

ELISPOT cell rescue.

Duncan A Meiklejohn1, R Karl Karlsson, Annika C Karlsson, Joan M Chapman, Douglas F Nixon, Becky Schweighardt.   

Abstract

The enzyme-linked immunospot (ELISPOT) assay is a highly sensitive and reproducible method for quantifying T cell-mediated immune responses, and has been used to measure antigen-specific responses post-vaccination. While there are several advantages of the ELISPOT assay for use in field settings for large-scale vaccination trials, blood draw volumes are often limited, and the number of antigen-specific responses that can be measured is constrained by the limited cell number. We reasoned that it should be possible to salvage and rescue viable cells from a completed ELISPOT assay post-incubation, to use for further experimentation. Here, we show that cells rescued from an ELISPOT plate after assay are viable, and may be used in a second cytokine-producing assay, in a proliferation assay, or to provide a source of DNA for genetic studies such as human leukocyte antigen (HLA) typing. Rescue of cells after an ELISPOT assay will be particularly useful for increasing sample utility and maximizing data collection from T cell assays in vaccine trials. Copyright 2004 Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15183092     DOI: 10.1016/j.jim.2004.03.006

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4.

Authors:  Jeffrey M Milush; Brian R Long; Jennifer E Snyder-Cappione; Amedeo J Cappione; Vanessa A York; Lishomwa C Ndhlovu; Lewis L Lanier; Jakob Michaëlsson; Douglas F Nixon
Journal:  Blood       Date:  2009-10-05       Impact factor: 22.113

2.  Strong human endogenous retrovirus-specific T cell responses are associated with control of HIV-1 in chronic infection.

Authors:  Devi SenGupta; Ravi Tandon; Raphaella G S Vieira; Lishomwa C Ndhlovu; Rachel Lown-Hecht; Christopher E Ormsby; Liyen Loh; R Brad Jones; Keith E Garrison; Jeffrey N Martin; Vanessa A York; Gerald Spotts; Gustavo Reyes-Terán; Mario A Ostrowski; Frederick M Hecht; Steven G Deeks; Douglas F Nixon
Journal:  J Virol       Date:  2011-04-27       Impact factor: 5.103

3.  T cells target APOBEC3 proteins in human immunodeficiency virus type 1-infected humans and simian immunodeficiency virus-infected Indian rhesus macaques.

Authors:  Stéphane Champiat; Keith E Garrison; Rui André Saraiva Raposo; Benjamin J Burwitz; Jason Reed; Ravi Tandon; Vanessa A York; Laura P Newman; Francesca A Nimityongskul; Nancy A Wilson; Rafael R Almeida; Jeffrey N Martin; Steven G Deeks; Michael G Rosenberg; Andrew A Wiznia; Gerald E Spotts; Christopher D Pilcher; Fredrick M Hecht; Mario A Ostrowski; Jonah B Sacha; Douglas F Nixon
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

4.  Transcriptional errors in human immunodeficiency virus type 1 generate targets for T-cell responses.

Authors:  Keith E Garrison; Stephane Champiat; Vanessa A York; Ashish T Agrawal; Esper G Kallas; Jeffrey N Martin; Frederick M Hecht; Steven G Deeks; Douglas F Nixon
Journal:  Clin Vaccine Immunol       Date:  2009-07-01

5.  Early initiation of combination antiretroviral therapy in HIV-1-infected newborns can achieve sustained virologic suppression with low frequency of CD4+ T cells carrying HIV in peripheral blood.

Authors:  Ari Bitnun; Lindy Samson; Tae-Wook Chun; Fatima Kakkar; Jason Brophy; Danielle Murray; Shawn Justement; Hugo Soudeyns; Mario Ostrowski; Shariq Mujib; P Richard Harrigan; John Kim; Paul Sandstrom; Stanley E Read
Journal:  Clin Infect Dis       Date:  2014-06-09       Impact factor: 9.079

6.  Immune escape mutations detected within HIV-1 epitopes associated with viral control during treatment interruption.

Authors:  Becky Schweighardt; Terri Wrin; Duncan A Meiklejohn; Gerald Spotts; Christos J Petropoulos; Douglas F Nixon; Frederick M Hecht
Journal:  J Acquir Immune Defic Syndr       Date:  2010-01       Impact factor: 3.731

7.  IL-2 immunotherapy to recently HIV-1 infected adults maintains the numbers of IL-17 expressing CD4+ T (T(H)17) cells in the periphery.

Authors:  Lishomwa C Ndhlovu; Elizabeth Sinclair; Lorrie Epling; Qi Xuan Tan; Terence Ho; Aashish R Jha; Ijeoma Eccles-James; Camilla Tincati; Jay A Levy; Douglas F Nixon; Frederick M Hecht; Jason D Barbour
Journal:  J Clin Immunol       Date:  2010-06-23       Impact factor: 8.317

8.  Influence of HAART on alternative reading frame immune responses over the course of HIV-1 infection.

Authors:  Stephane Champiat; Rui André Saraiva Raposo; Nicholas J Maness; John L Lehman; Sean E Purtell; Aaron M Hasenkrug; Jacob C Miller; Hansi Dean; Wayne C Koff; Marisa Ailin Hong; Jeffrey N Martin; Steven G Deeks; Gerald E Spotts; Christopher D Pilcher; Fredrick M Hecht; Esper G Kallas; Keith E Garrison; Douglas F Nixon
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

9.  Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot"

Authors:  Florian K Bihl; Elisabetta Loggi; John V Chisholm; Hannah S Hewitt; Leah M Henry; Caitlyn Linde; Todd J Suscovich; Johnson T Wong; Nicole Frahm; Pietro Andreone; Christian Brander
Journal:  J Transl Med       Date:  2005-05-11       Impact factor: 5.531

10.  T cell responses to human endogenous retroviruses in HIV-1 infection.

Authors:  Keith E Garrison; R Brad Jones; Duncan A Meiklejohn; Naveed Anwar; Lishomwa C Ndhlovu; Joan M Chapman; Ann L Erickson; Ashish Agrawal; Gerald Spotts; Frederick M Hecht; Seth Rakoff-Nahoum; Jack Lenz; Mario A Ostrowski; Douglas F Nixon
Journal:  PLoS Pathog       Date:  2007-11       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.